Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Jens, Bedke"'
Publikováno v:
Expert Opinion on Biological Therapy. 21:1215-1226
We have experienced several paradigm shifts and substantial changes in the treatment of metastatic renal cell carcinoma (mRCC) over the last two decades. Combination therapy with immune checkpoint inhibitors (ICI) as a dual combination (ICI-ICI) or w
Autor:
Michael B. Atkins, Dmitry Nosov, Lina Yin, L Rhoda Molife, Thomas Powles, Sergio J Azevedo, Jens Bedke, Satoshi Tamada, Elizabeth R. Plimack, Rustem Gafanov, Brian I. Rini, Delphine Borchiellini, Bohuslav Melichar, Denis Soulières, Ihor Vynnychenko, Mei Chen, Frédéric Pouliot, Viktor Stus, Raymond S. McDermott, T. Waddell
Publikováno v:
The Lancet Oncology. 21:1563-1573
The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here a
Autor:
Thomas Gauler, Manfred Johannsen, Carsten Grüllich, Viktor Grünwald, Jens Bedke, Nils Kroeger, Philipp Ivanyi
Publikováno v:
Journal of Cancer Research and Clinical Oncology
This letter summarizes recommendations from the interdisciplinary working group of renal tumors (IAGN) of the German Cancer Society for the systemic treatment of advanced/metastatic renal cell carcinoma in the context of the current SARS-CoV-2 pandem
Autor:
Koji Kawai, Satoshi Nagamori, Katherine M Bell-McGuinn, Cristiano Ferrario, Wen Pin Su, Isabel Syndikus, Aude Flechon, Georgios Gakis, Timothy Dudley Clay, Leticia Vazquez Cortés, Ronald de Wit, Florence Joly, Bozena Sikora-Kupis, Sergio Bracarda, Astra M. Liepa, Annemie Rutten, Daniel P. Petrylak, Su Peng Yeh, Annamaria Zimmermann, Sameera R. Wijayawardana, Mutsushi Kawakita, Siobhan Ng, Thean Hsiang Tan, Chikara Ohyama, Yu Jung Kim, Yuriy Golovko, Dimitrios Mavroudis, Jian Ri Li, Reinoud J. B. Blaisse, Mustafa Erman, Francesca Russo, Catherine Becht, Anghel Adrian Udrea, Robert Huddart, Syed A. Hussain, Fransiscus L.G. Erdkamp, Satoshi Fukasawa, Francesco Massari, Motohide Uemura, Boris Alekseev, Irfan Cicin, Se Hoon Park, Marcello Tucci, Lajos Géczi, Maureen J.B. Aarts, Yu Li Su, Fumimasa Fukuta, Hyo Jin Lee, Wolfgang Schultze-Seemann, Alexandra Drakaki, Hakan Harputluoglu, Xavier Garcia del Muro, Santhanam Sundar, Avivit Peer, Herlinde Dumez, William E. Lawler, Juan Ignacio Delgado Mignorance, Naveed Sarwar, Jeanny B. Aragon-Ching, Benjamin T. Herms, Fredrik Laestadius, Nobuaki Matsubara, Ivan Sinielnikov, Cora N. Sternberg, Hiroyuki Nishiyama, Piotr Tomczak, Brigitte Laguerre, Rebecca R. Hozak, Vasilis Karavasilis, Christina A. Schwentner, Hiroyuki Tsunemori, Masayoshi Nagata, Igor Bondarenko, Andrea Necchi, Yen Chuan Ou, Scott T. Tagawa, Constance Thibault, Richard A. Walgren, Akira Yokomizo, Evan Y. Yu, Alejo Rodriguez-Vida, Sufia Safina, Ulka N. Vaishampayan, János Révész, Aristotelis Bamias, Jae-Lyun Lee, Chien Liang Lin, Thomas W. Flaig, Roman Fomkin, Petr Alexandrovich Karlov, Joanna Wojcik-Tomaszewska, Junichi Inokuchi, Wataru Obara, Haralambos Kalofonos, John D. Hainsworth, Marc-Oliver Grimm, Thomas Eugene Lowe, Pablo Gajate Borau, Simon J. Crabb, Lisa Sengeloev, Junji Yonese, Simon Chowdhury, Elizabeth Jane Hovey, Daniel Castellano, Peter Istvan Acs, Chia-Chi Lin, Claudia Lorena Urzua Flores, Jean-Pascal Machiels, Kim N. Chi, Takahiro Osawa, Nobuo Shinohara, Daniel Kejzman, Günter Niegisch, David Sarid, Yuksel Urun, Yun Gyoo Lee, Oday Hamid, Alina Amalia Herzal, Michael Schenker, Eli Rosenbaum, Enrique Grande, Raya Leibowitz-Amit, Naoto Miyajima, Michiel S. van der Heijden, Shinichi Yamashita, Susanna Yee Shan Cheng, Kazuo Nishimura, Sun Young Rha, Thomas Powles, Hasan Şenol Coşkun, Jens Bedke, Ivor J. Percent, Christos Papandreou, James K. Schwarz, Masafumi Oyama, Giorgio V. Scagliotti, Chong-Xian Pan, Yoshihiko Tomita, Giampaolo Tortora, Stéphane Culine, Suet Lai Shirley Wong, Andrey Semenov, Jennifer L. Cultrera, Niels Viggo Jensen, Michael Stöckle, Katsuyoshi Hashine
Publikováno v:
Lancet Oncology, 21(1), 105-120. Lancet Publishing Group
The Lancet. Oncology, Vol. 21, no.1, p. 105-120 (2020)
Lancet oncology, 21(1), 105-120. Elsevier Science
lancet oncology, 21(1), 105-120. Lancet Publishing Group
The Lancet. Oncology, Vol. 21, no.1, p. 105-120 (2020)
Lancet oncology, 21(1), 105-120. Elsevier Science
lancet oncology, 21(1), 105-120. Lancet Publishing Group
Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary en
Autor:
Jens Bedke, Arnulf Stenzl, Thomas Zichner, Markus Zettl, Sven Mostböck, Henning Zelba, P. Anoop Chandran, Hans-Georg Rammensee, Cécile Gouttefangeas, Jörg Hennenlotter
Publikováno v:
Cancer Immunology Research. 7:1891-1899
Drugs targeting the programmed cell death protein 1 (PD-1) pathway are approved as therapies for an increasing number of cancer entities, including renal cell carcinoma. Despite a significant increase in overall survival, most treated patients do not
Publikováno v:
Expert Opinion on Biological Therapy. 20:83-94
Introduction: The systemic therapy in metastatic renal cell carcinoma (mRCC) is moving from tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors to immune checkpoin...
Publikováno v:
Expert opinion on biological therapy. 21(9)
The acquisition of resistance to VEGF-inhibiting therapies has prompted research toward immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC). Among several, checkpoint inhibitors including PD-1 and PD-L1 inhibitors are the most p
Autor:
Jens Bedke, Judith Wahrheit, Marcus Scharpf, Anna Reustle, Matthias Schwab, Elke Schaeffeler, Abbas Agaimy, Arndt Hartmann, Verena Klumpp, Steffen Rausch, Arnulf Stenzl, Stefan Winter, Pascale Fisel, Florian Büttner, Falko Fend, Jörg Hennenlotter, Denise Sonntag, Stephan Kruck
Publikováno v:
European Urology Focus. 5:608-618
Background Renal cell carcinoma (RCC) consists of prognostic distinct subtypes derived from different cells of origin (eg, clear cell RCC [ccRCC], papillary RCC [papRCC], and chromophobe RCC [chRCC]). ccRCC is characterized by lipid accumulation and
Autor:
Steffen Rausch, Jörg Hennenlotter, Elke Schaeffeler, Matthias Schwab, Stephan Kruck, Falko Fend, Peter Klaiber, Eva Neumann, Jens Bedke, Kathleen Freitag, Arnulf Stenzl, Marcus Scharpf
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 145:1835-1843
Based on the observation of beneficial effects on cancer metabolism, microenvironment, or VEGF-signaling, several non-anticancer drugs have been discussed as useful in renal cell carcinoma (RCC). In the present study, we investigated the prognostic i
Autor:
Yuzhuo Wang, Stephen Yiu Chuen Choi, Elke Schaeffeler, James Douglas, Jian Gao, Ladan Fazli, Craig Stewart, Ewan A. Gibb, Jörg Hennenlotter, Igor Moskalev, T. Hayashi, Arnulf Stenzl, Sebastian Frees, Pascale Fisel, Roland Seiler, Mads Daugaard, Htoo Zarni Oo, Jens Bedke, Peter C. Black, Nader Al Nakouzi, Tilman Todenhöfer, Matthias Schwab, Simroop Ladhar, Alireza Kamjabi
Publikováno v:
Molecular Cancer Therapeutics. 17:2746-2755
The significance of lactate transporters has been recognized in various cancer types, but their role in urothelial carcinoma remains mostly unknown. The aim of this study was to investigate the functional importance of the monocarboxylate transporter